
USD
$0.00
(0.00%
)At Close (As of Dec 11, 2025)
$41.25M
Market Cap
0.428
P/E Ratio
6
EPS
$14.20
52 Week High
$2.11
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $5.9M |
| Total Revenue | $17M |
| Cost Of Revenue | $11M |
| Costof Goods And Services Sold | $11M |
| Operating Income | -$37M |
| Selling General And Administrative | $31M |
| Research And Development | $13M |
| Operating Expenses | $43M |
| Investment Income Net | - |
| Net Interest Income | -$607K |
| Interest Income | - |
| Interest Expense | $607K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $268K |
| Income Before Tax | -$37M |
| Income Tax Expense | $725K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$38M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$36M |
| Ebitda | -$36M |
| Net Income | -$38M |
| Field | Value (USD) |
|---|---|
| Total Assets | $60M |
| Total Current Assets | $35M |
| Cash And Cash Equivalents At Carrying Value | $25M |
| Cash And Short Term Investments | $25M |
| Inventory | $4.1M |
| Current Net Receivables | $4M |
| Total Non Current Assets | $25M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $6K |
| Intangible Assets Excluding Goodwill | $6K |
| Goodwill | $6.9M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $2.2M |
| Other Non Current Assets | - |
| Total Liabilities | $28M |
| Total Current Liabilities | $12M |
| Current Accounts Payable | $3M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $2.1M |
| Total Non Current Liabilities | $16M |
| Capital Lease Obligations | $4M |
| Long Term Debt | $8.9M |
| Current Long Term Debt | $1M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $14M |
| Other Current Liabilities | $6.3M |
| Other Non Current Liabilities | $4.5M |
| Total Shareholder Equity | $32M |
| Treasury Stock | - |
| Retained Earnings | -$295M |
| Common Stock | $1.5M |
| Common Stock Shares Outstanding | $13M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $5.9M |
| Total Revenue | $17M |
| Cost Of Revenue | $11M |
| Costof Goods And Services Sold | $11M |
| Operating Income | -$37M |
| Selling General And Administrative | $31M |
| Research And Development | $13M |
| Operating Expenses | $43M |
| Investment Income Net | - |
| Net Interest Income | -$607K |
| Interest Income | - |
| Interest Expense | $607K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $268K |
| Income Before Tax | -$37M |
| Income Tax Expense | $725K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$38M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$36M |
| Ebitda | -$36M |
| Net Income | -$38M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Veru Inc. is a clinical-stage biopharmaceutical company based in Miami, Florida, focused on developing innovative therapeutics primarily for oncology and unmet medical needs. The company's robust pipeline features a range of drug candidates designed to tackle various cancers, emphasizing both novel therapies and improvements to existing treatments. By leveraging its proprietary technologies and scientific acumen, Veru is dedicated to advancing patient care and delivering potentially life-saving solutions while enhancing shareholder value. With a commitment to addressing critical healthcare challenges, Veru positions itself at the forefront of biopharmaceutical innovation.